---
title: "China Traditional Chinese Medicine Forecasts Swings to 2025 Losses"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273935006.md"
description: "China Traditional Chinese Medicine Forecasts Swings to 2025 Losses"
datetime: "2026-01-28T04:47:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273935006.md)
  - [en](https://longbridge.com/en/news/273935006.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273935006.md)
---

# China Traditional Chinese Medicine Forecasts Swings to 2025 Losses



### Related Stocks

- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [00570.HK](https://longbridge.com/en/quote/00570.HK.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [159929.CN](https://longbridge.com/en/quote/159929.CN.md)
- [589720.CN](https://longbridge.com/en/quote/589720.CN.md)
- [513200.CN](https://longbridge.com/en/quote/513200.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)

## Related News & Research

- [Fosun Pharma Unit Gets China Nod for Amyloidosis Drug Trial](https://longbridge.com/en/news/282675084.md)
- [Guangdong HEC Pharma files HKEX return, repurchases shares at HKD 44.26](https://longbridge.com/en/news/282671748.md)
- [Pharmaron Beijing to release first-quarter results after board meeting](https://longbridge.com/en/news/282667108.md)
- [RemeGen Drug Approved For Cancer Indication](https://longbridge.com/en/news/282478668.md)
- [Cutia Therapeutics’ Botox Rival Meets Phase III Goals in China](https://longbridge.com/en/news/282464943.md)